利特昔替尼治疗斑秃见效果的时间

Introduction: Ritexitinib is a kinase inhibitor that inhibits tyrosine kinases expressed in the Janus kinase 3 (JAK3) and hepatocellular carcinoma (TEC) kinase families. Inhibition of JAK3 and TEC kinase family members by ritexitinib may block cytokine signaling and the cytolytic activity of T cells, which is related to the pathogenesis of alopecia areata. The efficacy of ritexitinib in the treatment of alopecia areata can be observed in a relatively short period of time.

Indications

It is a kinase inhibitor indicated for the treatment of severe alopecia areata in adults and adolescents aged 12 years and above. It is also being evaluated for vitiligo, Crohn's disease and ulcerative colitis. Alopecia areata is an autoimmune hair loss disease that brings a huge physical and mental burden to patients. As a new drug for the treatment of alopecia areata, ritexitinib provides patients with a new treatment option.

Marketing status

On June 23, 2023, ritlecitinib was approved in the United States for the treatment of severe alopecia areata in adults and adolescents 12 years and older. On October 19, 2023, the China State Food and Drug Administration approved the marketing of ritexitinib. The approved indications are adolescents and adults with severe alopecia areata aged 12 years and above.

How long does it take for ritixitinib to be effective in the treatment of alopecia areata

Nearly 25% of adults and adolescents with alopecia areata treated with ritixitinib saw significant hair regrowth covering 80% or more of their scalp in less than 6 months. Additionally, 13.4% of people taking rituxitinib had scalp hair coverage of 90% or more.

In addition, after 24 weeks of treatment, 49.2% of patients had moderate to great improvement in alopecia areata. These data indicate that ritixitinib can produce significant hair regrowth in patients with alopecia areata within approximately 6 months. However, each patient's response may vary, and treatment effectiveness is affected by individual differences.

Medication Guide

The recommended dose of ritexitinib is 50 mg, taken orally once a day, with or without food. Treatment should be interrupted if the absolute lymphocyte count (ALC) is <500/mm³ and treatment should be discontinued if the platelet count is <50,000/mm³. Temporary interruptions of treatment for less than 6 weeks are not expected to result in significant loss of regenerated scalp hair.

Safety and Tolerability

Clinical trials of ritixitinib have shown that the drug is safe and well tolerated, with no deaths reported, and no dose-dependent trends in serious adverse events, severe adverse events, or treatment-related adverse events leading to discontinuation.